{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:24:25Z","timestamp":1792110265030,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title\/>\n                  <jats:p>In this clinical perspective, we examine the role of gonadotropin-releasing hormone (GnRH) antagonist combination therapies in the management of uterine leiomyomas during perimenopause, a period marked by hormonal variability and heightened symptom burden. Drawing on mechanistic comparisons, randomized trial data, and long-term safety findings, we review evidence demonstrating that GnRH antagonist combination therapies provide rapid, reversible suppression of gonadotropin secretion without an estrogen flare. This, in turn, results in consistent reductions in heavy menstrual bleeding associated with leiomyomas, management of bulk-related symptoms, and improvement with anemia. We further highlight limitations of conventional hormonal and expectant management strategies during perimenopause and discuss practical considerations for patient selection and monitoring. Collectively, these findings support GnRH antagonist combination therapy as a targeted, time-limited, and well-tolerated treatment option that addresses a critical therapeutic gap for perimenopausal patients with symptomatic uterine leiomyomas.<\/jats:p>","DOI":"10.1097\/aog.0000000000006399","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:00:16Z","timestamp":1786654816000},"page":"e289-e295","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Gonadotropin-Releasing Hormone Antagonist Combination Therapies for Perimenopausal Uterine Leiomyoma Care"],"prefix":"10.1097","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8189-0208","authenticated-orcid":false,"given":"Jane Q.","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-5866","authenticated-orcid":false,"given":"Shannon K.","family":"Laughlin-Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"R1-20261015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in Black and White women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20261015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/AOG.0000000000005145","article-title":"Oral gonadotropin-releasing hormone antagonists for the treatment of uterine leiomyomas","volume":"141","author":"Neblett","year":"2023","journal-title":"Obstet Gynecol"},{"key":"R3-20261015","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMcp2309623","article-title":"Uterine fibroids","volume":"391","author":"Stewart","year":"2024","journal-title":"N Engl J Med"},{"key":"R4-20261015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0378-5122(93)90026-E","article-title":"Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone","volume":"18","author":"Hee","year":"1993","journal-title":"Maturitas"},{"key":"R5-20261015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/AOG.0b013e31817d452b","article-title":"The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause","volume":"112","author":"Van Voorhis","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R6-20261015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijgo.70497","article-title":"Medical treatment of fibroids: FIGO best practice guidance","volume":"171","author":"Diaz","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"R7-20261015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/IJWH.S442357","article-title":"Oral GnRH antagonists in combination with estradiol and norethindrone acetate for pain relief associated with endometriosis: a review of evidence of a novel class of hormonal agents","volume":"16","author":"Othman","year":"2024","journal-title":"Int J Womens Health"},{"key":"R8-20261015","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.fertnstert.2025.03.025","article-title":"Gonadotropin-releasing hormone antagonists: a prompt to early use in the hormonal treatment of gynecologic disease","volume":"123","author":"Taylor","year":"2025","journal-title":"Fertil Steril"},{"key":"R9-20261015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(22)01475-1","article-title":"Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials","volume":"400","author":"Donnez","year":"2022","journal-title":"Lancet"},{"key":"R10-20261015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.fertnstert.2024.05.004","article-title":"Advances in uterine fibroid research: linking progesterone and the transforming growth factor-\u03b2 signaling pathway","volume":"122","author":"Islam","year":"2024","journal-title":"Fertil Steril"},{"key":"R11-20261015","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-023-01958-6","article-title":"Current and emerging treatment options for uterine fibroids","volume":"83","author":"Ali","year":"2023","journal-title":"Drugs"},{"key":"R12-20261015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20261015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"R14-20261015","doi-asserted-by":"crossref","first-page":"320.e1","DOI":"10.1016\/j.ajog.2022.11.1278","article-title":"Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials","volume":"228","author":"Stewart","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"R15-20261015","first-page":"1217","article-title":"An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial","volume":"76","author":"Carr","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20261015","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/dead263","article-title":"Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study","volume":"39","author":"Becker","year":"2024","journal-title":"Hum Reprod"},{"key":"R17-20261015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.fertnstert.2017.05.006","article-title":"Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study","volume":"108","author":"Archer","year":"2017","journal-title":"Fertil Steril"},{"issue":"3, suppl","key":"R18-20261015","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.fertnstert.2021.07.038","article-title":"Assessment of common adverse events of Relugolix combination therapy in premenopausal women treated for symptomatic estrogen-driven conditions: liberty and spirit studies","volume":"116","author":"Al-Hendy","year":"2021","journal-title":"Fertil Sterility"},{"key":"R19-20261015","doi-asserted-by":"crossref","first-page":"630.e1","DOI":"10.1016\/j.ajog.2024.06.040","article-title":"Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial","volume":"231","author":"Miller","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"R20-20261015","doi-asserted-by":"crossref","first-page":"662.e1","DOI":"10.1016\/j.ajog.2023.08.030","article-title":"LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids","volume":"229","author":"Al-Hendy","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"R23-20261015","doi-asserted-by":"crossref","first-page":"1629834","DOI":"10.3389\/frph.2025.1629834","article-title":"The epidemiology of uterine fibroids: global disease burden from 1990 to 2021 and future trend predictions","volume":"7","author":"Wu","year":"2025","journal-title":"Front Reprod Health"},{"key":"R24-20261015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/ph18010036","article-title":"GnRH peptide antagonist: comparative analysis of chemistry and formulation with implications for clinical safety and efficacy","volume":"18","author":"Patel","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R25-20261015","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.fertnstert.2024.12.031","article-title":"Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials","volume":"123","author":"Donnez","year":"2025","journal-title":"Fertil Sterility"},{"key":"R26-20261015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.fertnstert.2025.06.016","article-title":"Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study","volume":"124","author":"Donnez","year":"2025","journal-title":"Fertil Sterility"},{"key":"R27-20261015","doi-asserted-by":"crossref","first-page":"19887","DOI":"10.1073\/pnas.0808188105","article-title":"Growth of uterine leiomyomata among premenopausal Black and White women","volume":"105","author":"Peddada","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R28-20261015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.fertnstert.2025.04.037","article-title":"Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2","volume":"124","author":"Catherino","year":"2025","journal-title":"Fertil Steril"},{"key":"R29-20261015","doi-asserted-by":"crossref","first-page":"2237121","DOI":"10.1080\/09513590.2023.2237121","article-title":"Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix","volume":"39","author":"Yamanaka","year":"2023","journal-title":"Gynecol Endocrinol"},{"key":"R30-20261015","first-page":"338","article-title":"Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis","volume":"2","author":"Muneyyirci-Delale","year":"2021","journal-title":"F S Rep"},{"key":"R31-20261015","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.3390\/jcm10245794","article-title":"Uterine adenomyosis treated by linzagolix, an oral gonadotropin-releasing hormone receptor antagonist: a pilot Study with a new 'Hit Hard First and then Maintain' regimen of administration","volume":"10","author":"Donnez","year":"2021","journal-title":"J Clin Med"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:01:15Z","timestamp":1792069275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006399","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"2026-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}